190 related articles for article (PubMed ID: 29522296)
21. Circulating irisin levels and muscle FNDC5 mRNA expression are independent of IL-15 levels in mice.
Quinn LS; Anderson BG; Conner JD; Wolden-Hanson T
Endocrine; 2015 Nov; 50(2):368-77. PubMed ID: 25920499
[TBL] [Abstract][Full Text] [Related]
22. Plasma levels of cellular fibronectin in patients with localized and metastatic renal cell carcinoma.
Hegele A; Heidenreich A; Kropf J; von Knobloch R; Varga Z; Hofmann R; Olbert P
Tumour Biol; 2004; 25(3):111-6. PubMed ID: 15361707
[TBL] [Abstract][Full Text] [Related]
23. Effects of Dietary Macronutrient Composition on FNDC5 and Irisin in Mice Skeletal Muscle.
de Macêdo SM; Lelis DF; Mendes KL; Fraga CAC; Brandi IV; Feltenberger JD; Farias LC; Guimarães ALS; de Paula AMB; Santos SHS
Metab Syndr Relat Disord; 2017 May; 15(4):161-169. PubMed ID: 28437200
[TBL] [Abstract][Full Text] [Related]
24. Irisin and Carcinoembryonic Antigen (CEA) as Potential Diagnostic Biomarkers in Gastric and Colorectal Cancers.
Abd Temur A; Aqeel Rashid F
Rep Biochem Mol Biol; 2021 Oct; 10(3):488-494. PubMed ID: 34981027
[TBL] [Abstract][Full Text] [Related]
25. Serum ferritin: a tumor marker for renal cell carcinoma.
Essen A; Ozen H; Ayhan A; Ergen A; Tasar C; Remzi F
J Urol; 1991 Jun; 145(6):1134-7. PubMed ID: 2033679
[TBL] [Abstract][Full Text] [Related]
26. Use of quantitative shotgun proteomics to identify fibronectin 1 as a potential plasma biomarker for clear cell carcinoma of the kidney.
Yokomizo A; Takakura M; Kanai Y; Sakuma T; Matsubara J; Honda K; Naito S; Yamada T; Ono M
Cancer Biomark; 2011-2012; 10(3-4):175-83. PubMed ID: 22674303
[TBL] [Abstract][Full Text] [Related]
27. Circulating mitochondrial DNA in serum: a universal diagnostic biomarker for patients with urological malignancies.
Ellinger J; Müller DC; Müller SC; Hauser S; Heukamp LC; von Ruecker A; Bastian PJ; Walgenbach-Brunagel G
Urol Oncol; 2012; 30(4):509-15. PubMed ID: 20870429
[TBL] [Abstract][Full Text] [Related]
28. Combined training, FNDC5/irisin levels and metabolic markers in obese men: A randomised controlled trial.
Bonfante IL; Chacon-Mikahil MP; Brunelli DT; Gáspari AF; Duft RG; Lopes WA; Bonganha V; Libardi CA; Cavaglieri CR
Eur J Sport Sci; 2017 Jun; 17(5):629-637. PubMed ID: 28287024
[TBL] [Abstract][Full Text] [Related]
29. Serum carbonic anhydrase 9 level is associated with postoperative recurrence of conventional renal cell cancer.
Li G; Feng G; Gentil-Perret A; Genin C; Tostain J
J Urol; 2008 Aug; 180(2):510-3; discussion 513-4. PubMed ID: 18550116
[TBL] [Abstract][Full Text] [Related]
30. Serum Irisin Predicts Mortality Risk in Acute Heart Failure Patients.
Shen S; Gao R; Bei Y; Li J; Zhang H; Zhou Y; Yao W; Xu D; Zhou F; Jin M; Wei S; Wang K; Xu X; Li Y; Xiao J; Li X
Cell Physiol Biochem; 2017; 42(2):615-622. PubMed ID: 28595171
[TBL] [Abstract][Full Text] [Related]
31. Common single nucleotide polymorphisms in the FNDC5 gene and serum irisin levels in acute myocardial infarction.
Önalan Etem E; Diş Ö; Tektemur A; Korkmaz H; Buran Kavuran İ
Anatol J Cardiol; 2021 Aug; 25(8):528-535. PubMed ID: 34369880
[TBL] [Abstract][Full Text] [Related]
32. Correlation of bFGF expression in renal cell cancer with clinical and histopathological features by tissue microarray analysis and measurement of serum levels.
Horstmann M; Merseburger AS; von der Heyde E; Serth J; Wegener G; Mengel M; Feil G; Hennenlotter J; Nagele U; Anastasiadis A; Bokemeyer C; Stenzl A; Kuczyk M
J Cancer Res Clin Oncol; 2005 Nov; 131(11):715-22. PubMed ID: 16080018
[TBL] [Abstract][Full Text] [Related]
33. Maternal and neonatal irisin precursor gene FNDC5 polymorphism is associated with preterm birth.
Salem H; Yatchenko Y; Anosov M; Rosenfeld T; Altarescu G; Grisaru-Granovsky S; Birk R
Gene; 2018 Apr; 649():58-62. PubMed ID: 29408625
[TBL] [Abstract][Full Text] [Related]
34. Quantification of carbonic anhydrase IX expression in serum and tissue of renal cell carcinoma patients using enzyme-linked immunosorbent assay: prognostic and diagnostic potentials.
Zhou GX; Ireland J; Rayman P; Finke J; Zhou M
Urology; 2010 Feb; 75(2):257-61. PubMed ID: 19963243
[TBL] [Abstract][Full Text] [Related]
35. Circulating adiponectin as a biomarker in renal cell carcinoma: a systematic review and meta-analysis.
Yap NY; Yap FN; Perumal K; Rajandram R
Biomarkers; 2019 Sep; 24(6):607-614. PubMed ID: 31215811
[No Abstract] [Full Text] [Related]
36. Circulating levels of irisin is elevated in hypothyroidism, a case-control study.
Ateş İ; Altay M; Topçuoğlu C; Yılmaz FM
Arch Endocrinol Metab; 2016 Apr; 60(2):95-100. PubMed ID: 26201007
[TBL] [Abstract][Full Text] [Related]
37. Serum levels of HMGB1 have a diagnostic role in metastatic renal cell cancer.
Kargı A; Demirpençe Ö; Gündüz Ş; Göktaş S; Alikanoǧlu AS; Yıldırım M
Cancer Biomark; 2016 Apr; 17(1):17-20. PubMed ID: 27062570
[TBL] [Abstract][Full Text] [Related]
38. Irisin - a myth rather than an exercise-inducible myokine.
Albrecht E; Norheim F; Thiede B; Holen T; Ohashi T; Schering L; Lee S; Brenmoehl J; Thomas S; Drevon CA; Erickson HP; Maak S
Sci Rep; 2015 Mar; 5():8889. PubMed ID: 25749243
[TBL] [Abstract][Full Text] [Related]
39. The diagnostic and prognostic roles of serum irisin in bladder cancer.
Esawy MM; Abdel-Samd KM
Curr Probl Cancer; 2020 Aug; 44(4):100529. PubMed ID: 32139156
[TBL] [Abstract][Full Text] [Related]
40. The pyruvate kinase isoenzyme tumor M2 (Tu M2-PK) as a tumor marker for renal carcinoma.
Oremek GM; Teigelkamp S; Kramer W; Eigenbrodt E; Usadel KH
Anticancer Res; 1999; 19(4A):2599-601. PubMed ID: 10470201
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
